AstraZeneca: What The Market's Missing

Morsa Images/DigitalVision via Getty Images Over the last twelve months, investors applauded as the S&P 500 climbed over 21%. Unfortunately, investors in AstraZeneca (NASDAQ:AZN) don’t have much to clap about. Shares in that company are down nearly 8% over the trailing twelve months. The poor results are in part due to slowing sales of AZN’s Covid-19 vaccine. However, investors looking past that transitory headwind will find there is much to like about the company’s prospects. AZN has a strong pipeline, ...